229 related articles for article (PubMed ID: 14654687)
21. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Wrapp D; Wang N; Corbett KS; Goldsmith JA; Hsieh CL; Abiona O; Graham BS; McLellan JS
Science; 2020 Mar; 367(6483):1260-1263. PubMed ID: 32075877
[TBL] [Abstract][Full Text] [Related]
22. Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer.
Zhai Y; Sun F; Li X; Pang H; Xu X; Bartlam M; Rao Z
Nat Struct Mol Biol; 2005 Nov; 12(11):980-6. PubMed ID: 16228002
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.
Yin W; Mao C; Luan X; Shen DD; Shen Q; Su H; Wang X; Zhou F; Zhao W; Gao M; Chang S; Xie YC; Tian G; Jiang HW; Tao SC; Shen J; Jiang Y; Jiang H; Xu Y; Zhang S; Zhang Y; Xu HE
Science; 2020 Jun; 368(6498):1499-1504. PubMed ID: 32358203
[TBL] [Abstract][Full Text] [Related]
24. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors.
Kirchdoerfer RN; Ward AB
Nat Commun; 2019 May; 10(1):2342. PubMed ID: 31138817
[TBL] [Abstract][Full Text] [Related]
25. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
26. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.
Lung J; Lin YS; Yang YH; Chou YL; Shu LH; Cheng YC; Liu HT; Wu CY
J Med Virol; 2020 Jun; 92(6):693-697. PubMed ID: 32167173
[TBL] [Abstract][Full Text] [Related]
27. Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2'-O-methyltransferase nsp10/nsp16 complex.
Decroly E; Debarnot C; Ferron F; Bouvet M; Coutard B; Imbert I; Gluais L; Papageorgiou N; Sharff A; Bricogne G; Ortiz-Lombardia M; Lescar J; Canard B
PLoS Pathog; 2011 May; 7(5):e1002059. PubMed ID: 21637813
[TBL] [Abstract][Full Text] [Related]
28. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing.
Eckerle LD; Becker MM; Halpin RA; Li K; Venter E; Lu X; Scherbakova S; Graham RL; Baric RS; Stockwell TB; Spiro DJ; Denison MR
PLoS Pathog; 2010 May; 6(5):e1000896. PubMed ID: 20463816
[TBL] [Abstract][Full Text] [Related]
29. A Comprehensive Update of Anti-COVID-19 Activity of Heterocyclic Compounds.
Nazir MS; Ahmad M; Aslam S; Rafiq A; Al-Hussain SA; Zaki MEA
Drug Des Devel Ther; 2024; 18():1547-1571. PubMed ID: 38737333
[TBL] [Abstract][Full Text] [Related]
30. Favipiravir Analogues as Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase, Combined Quantum Chemical Modeling, Quantitative Structure-Property Relationship, and Molecular Docking Study.
Latosińska M; Latosińska JN
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257352
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of RdRp of SARS-CoV-2 through artificial intelligence and machine learning utilizing structure-based drug design strategy.
Imtiaz F; Pasha MK
Turk J Chem; 2022; 46(3):583-594. PubMed ID: 37720604
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 prevalence in domestic and wildlife animals: A genomic and docking based structural comprehensive review.
Das T; Sikdar S; Chowdhury MHU; Nyma KJ; Adnan M
Heliyon; 2023 Sep; 9(9):e19345. PubMed ID: 37662720
[TBL] [Abstract][Full Text] [Related]
33. Green and rapid and instrumental one-pot method for the synthesis of imidazolines having potential anti-SARS-CoV-2 main protease activity.
Azimi S; Merza MS; Ghasemi F; Dhahi HA; Baradarbarjastehbaf F; Moosavi M; Kargar PG; Len C
Sustain Chem Pharm; 2023 Sep; 34():101136. PubMed ID: 37333050
[TBL] [Abstract][Full Text] [Related]
34. A special satellite-like RNA of a novel hypovirus from Pestalotiopsis fici broadens the definition of fungal satellite.
Han Z; Liu J; Kong L; He Y; Wu H; Xu W
PLoS Pathog; 2023 Jun; 19(6):e1010889. PubMed ID: 37285391
[TBL] [Abstract][Full Text] [Related]
35. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.
Xue Y; Mei H; Chen Y; Griffin JD; Liu Q; Weisberg E; Yang J
MedComm (2020); 2023 Jun; 4(3):e254. PubMed ID: 37193304
[TBL] [Abstract][Full Text] [Related]
36. Novel α-aminophosphonate derivates synthesis, theoretical calculation, Molecular docking, and in silico prediction of potential inhibition of SARS-CoV-2.
Kerkour R; Chafai N; Moumeni O; Chafaa S
J Mol Struct; 2023 Jan; 1272():134196. PubMed ID: 36193287
[TBL] [Abstract][Full Text] [Related]
37. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.
Yang KS; Leeuwon SZ; Xu S; Liu WR
J Med Chem; 2022 Jul; 65(13):8686-8698. PubMed ID: 35731933
[TBL] [Abstract][Full Text] [Related]
38. Seeking antiviral drugs to inhibit SARS-CoV-2 RNA dependent RNA polymerase: A molecular docking analysis.
Khater I; Nassar A
PLoS One; 2022; 17(5):e0268909. PubMed ID: 35639751
[TBL] [Abstract][Full Text] [Related]
39. Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2.
Koulgi S; Jani V; Uppuladinne MVN; Sonavane U; Joshi R
RSC Adv; 2020 Jul; 10(45):26792-26803. PubMed ID: 35515752
[TBL] [Abstract][Full Text] [Related]
40. Coronavirus enzyme inhibitors-experimentally proven natural compounds from plants.
Park J; Park R; Jang M; Park YI; Park Y
J Microbiol; 2022 Mar; 60(3):347-354. PubMed ID: 35089586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
